(Q37678436)

21 August 2017

1 reference

title

A review of erlotinib--an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor (English)

1 reference

21 August 2017

Renuka Iyer

1

1 reference

21 August 2017

Anubha Bharthuar

series ordinal

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 February 2010

1 reference

Expert Opinion on Pharmacotherapy

21 August 2017

published in

1 reference

21 August 2017

volume

11

1 reference

21 August 2017

issue

2

1 reference

21 August 2017

page(s)

311-320

1 reference

Receptor tyrosine kinases and anticancer therapy

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656560903551283

The EGF receptor family as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903551283

Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903551283

Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903551283

Pharmacokinetics of erlotinib for the treatment of high-grade glioma in a pediatric patient with cystic fibrosis: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903551283

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903551283

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903551283

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903551283

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903551283

Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903551283

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903551283

Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903551283

Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903551283

Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903551283

Phase II study of erlotinib in patients with advanced biliary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903551283

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903551283

Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903551283

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903551283

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903551283

Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903551283

10.1517/14656560903551283

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference